<DOC>
	<DOCNO>NCT02819271</DOCNO>
	<brief_summary>This study design assess safe dosage drug CXL-1427 ( BMS-986231 ) healthy volunteer .</brief_summary>
	<brief_title>A First-in-Human Study Safety Single Continuous Intravenous ( IV ) Infusions CXL-1427 48 Hours Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>No evidence acute chronic health disorder Not take prescription medication within 15 day study entry Not take overthecounter medication herbal/vitamin supplement within 3 day study entry Not dietary restriction Have body mass index ( BMI ) ≥18 ≤34 Weigh least 50kg ( 110 pound ) Be current recent ( within 6 month Screening Visit ) smoker user nicotinecontaining product Have history symptomatic hypotension , orthostatic hypotension syncope Have history headache symptoms attributable caffeine withdrawal Have history bleed diathesis Have positive serology screen HIV antibody , hepatitis B surface antigen hepatitis C antibody screen Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>